Das pharmakologische Profil von Sildenafil zeigt neben der PDE5-Inhibition auch eine geringe Aktivität an der PDE6 in der Retina. Dies erklärt visuelle Nebenwirkungen wie Farbsehstörungen, die gelegentlich auftreten. Die orale Bioverfügbarkeit beträgt etwa 40 %, mit einer hohen Bindung an Plasmaproteine. Das Verteilungsvolumen ist groß, sodass die Substanz rasch in verschiedene Gewebe gelangt. Die Metabolisierung erfolgt hepatisch und produziert einen aktiven Metaboliten, der die pharmakologische Wirkung ergänzt. Nebenwirkungen sind dosisabhängig und umfassen Kopfschmerzen, Hautrötung und Dyspepsie. Bei Vergleichen innerhalb der Wirkstoffklasse wird viagra original regelmäßig als Beispiel für eine Substanz mit schneller, aber kurzzeitiger Wirkung aufgeführt.

Dragon’s blood

Unique Topical
Products
for the Relief of
Skin Conditions
Southeast Virginia
Technology Partnership Forum
June 15, 2010
43% of al reported skin
 Any scratch, rash, bug bite, cut, abrasion, skin break
 Contact with an infected person or any surface
Surgery / hospital; elderly, nursing homes, diabetics, gyms www.dalosbio.com
Molluscum Contagiosum
 Contact with an infected person or any surface
 Day care centers, gyms, other child-friendly locations  Extreme problem for pediatricians and dermatologists www.dalosbio.com
MersaDermTM – for MRSA and other
skin infections
 90% increase in 10 years; over 200 M reported cases  More US deaths from MRSA than from AIDS  Average cost - $60 K / patient and $5 M / hospital  Drug resistance –> Bactroban / oral antibiotics  MersaDerm meets the growing unmet need
www.dalosbio.com
PoxiDermTM – for
Molluscum Contagiosum
 200 M cases worldwide and rising rapidly  Normal treatment is to scrape, cut, burn, freeze,  Pox (smal pox) family – benign but persistent  Dermatologists and Pediatricians at a loss  No effective antiviral available until PoxiDerm
www.dalosbio.com
Dalos Business Description
 BIO Award as “most innovative and commercializable”  Direct to Market, evidence-based products  75% increase in sales from Year 1 to Year 2 www.dalosbio.com
Competition
 Bactroban – drug resistance; same with oral Neosporin – no MRSA activity  No active topical products (or oral) Abhorrent in-office procedures Internet “remedies” with no basis www.dalosbio.com
Dalos Marketing Strategies
 Great responses at American Academy of Dermatology and  Drive consumers to internet store – www.dalosbio.com
 Traditional Distribution Channels (Chain stores)  Social Networking (Facebook, WebMD, internet sites) www.dalosbio.com
Dalos Partnering Strategies
 Like-focused companies in US and world  Military (many military applications) www.dalosbio.com
Other Dalos Products
 Shampoo, body wash, hand soap Now being purchased with MersaDerm and PoxiDerm www.dalosbio.com
Management Team
 Dr. Gary Pekoe – President & CEO  28 years pharma / biotech product development Scientific Advisory Committee
 James Leyden, MD, U of Pennsylvania Judith Wil iams, MD, Eastern Virginia Medical School Dennis West, PhD, Northwestern University Arnold Oppenheim, MD, VA Beach Dermatology Knox Van Dyke, PhD, West Virginia U www.dalosbio.com
U.S. Projections
MersaDerm Skin infections $ 1.2 BPoxiDerm  Al other products in pipeline add to upside  Figures based on achieving investment goals www.dalosbio.com
www.dalosbio.com
Conclusions
 We solve the problem with MRSA, Mol uscum Gary Pekoe, PhD
888 321-MRSA (6772)
[email protected]
www.dalosbio.com

Source: http://www.flcmidatlantic.org/pdf/BiomedtechForum-06152010/DalosBioPharma.pdf